

February 15, 2018

Basaglar Preferred Long Acting Insulin for Minnesota Health Care Programs Formulary - *Effective April 1, 2018*

This bulletin provides notice for a formulary change to coverage of long acting insulin products on the UCare Minnesota State Health Care Programs formulary impacting the following UCare products: *UCare Connect* (SNBC), MinnesotaCare, Prepaid Medical Assistance Program (PMAP), and Minnesota Senior Care Plus (MSC Plus).

Effective April 1, 2018, Basaglar will become the sole preferred option for long acting insulin products. Lantus SoloStar pen and Lantus vials will become non-formulary products, and all members will be required to switch to Basaglar unless a formulary exception is obtained. Toujeo, Tresiba and Levemir will remain as non-formulary products.

Formulary exceptions can be requested starting April 1, 2018, if a switch to Basaglar is not medically appropriate for a particular member. Formulary exceptions may be requested through Express Scripts by phone at 1-800-753-2851 or by fax at 1-877-251-5896.

In February and March 2018, UCare will send letters to members and providers impacted by these changes to initiate treatment adjustments, if appropriate, prior to the effective date. The purpose of the change is to promote the most cost-effective product on our Minnesota Health Care Programs formulary.

Questions?

If you have further questions, please call UCare's Provider Assistance Center at 612-676-3300 or 1-888-531-1493 toll free.